Natera, Inc. Enters an Amendment and Waiver to its Credit Agreement with OrbiMed Royalty Opportunities II, L.P
January 07, 2019 at 04:19 pm EST
Share
On December 31, 2018, Natera, Inc. entered into an amendment and waiver to its credit agreement dated August 8, 2017 with OrbiMed Royalty Opportunities II, L.P. The Credit Agreement provides for a $100,000,000 senior secured term loan facility, of which $75,000,000 was provided to Natera in August 2017 and the remaining $25,000,000 was to be provided at Natera’s request no later than December 31, 2018. The Amendment increased the amount of the Delayed Draw to $50,000,000 and extended the deadline for the Delayed Draw to March 31, 2019. Upon the Delayed Draw, if any, the interest rate for the Loans will decrease to the sum of (i) 8.50% plus (ii) the higher of (x) the LIBO Rate for such Interest Period and (y) 1.00.
Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of womenâs health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Companyâs algorithms and bioinformatics in order to validate and launch tests based on the Companyâs technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
NATERA, INC. 
